AI-First Drug Design: Accelerating the Discovery of New Therapeutics
Flash Talk with Rebecca Paul, Ph.D.
Hosted by Drug Hunter's Director of Industry Research & Relations Dennis Koester, Ph.D.
December 12 2024 at 8 AM PDT / 11 AM EDT / 5 PM CEST
Isomorphic Labs is a digital biology company working to reimagine drug discovery with the power and pace of artificial intelligence. The company was founded with the belief that cutting-edge computational and AI methods hold the potential to transform drug design.
In this Flash Talk, Rebecca Paul, Head of Medicinal Drug Design at Iso, will share her insights on how the company is applying AlphaFold 3 along with other breakthrough AI models developed at Isomorphic Labs, to advance the rational design and optimisation of small molecules.
Rebecca Paul is a Senior Research Leader at Isomorphic Labs. She holds an MA in Natural Sciences from the University of Cambridge and a PhD from Imperial College London. After her PhD, she moved to Heptares Therapeutics (now Nxera Pharma), working on GPCRs across a range of modalities and disease indications. Her first experience working in the AI drug design space was at BenevolentAI, where she led projects in the neurodegeneration field. Rebecca joined Isomorphic Labs in 2022, where she leads the Medicinal Drug Design Group. To date, Rebecca has worked on 6 projects which have reached candidate selection or beyond.